• Matica (MMJ) subsidiary West Island introduces a new brand to the non-medical cannabis market in B.C.
  • West Island is also the maker of the popular OUEST™ brand of premium cannabis
  • CITOYEN™ brand products are quality cannabis offerings at lower entry prices and with greater volumes in comparison to its premium OUEST™ products
  • Matica is a multi-faceted, innovative company in the Québec cannabis space
  • Matica Enterprises Inc. (MMJ) is down 14.29 per cent and is trading at C$0.03 at 9:38 am PT

Matica Enterprises (MMJ) subsidiary, RoyalMax Biotechnology Canada is launching the CITOYEN™ brand of cannabis in B.C.

West Island is also the maker of the popular OUEST™ brand of premium cannabis.

CITOYEN™ brand products are quality cannabis offerings at lower entry prices and with greater volumes in comparison to its premium OUEST™ products.

“CITOYEN™ is the French term for citizen. As the name suggests, this is a flower that is accessible to all. It strives to provide consumers with a high-quality bud at a price that is affordable to all, truly The People’s Flower,” stated Boris Ziger, CEO, Matica.

“Available in large size formats, our CITOYEN™ brand provides consumers what they have been asking for,” he added.

Matica is a multi-faceted, innovative company in the Québec cannabis space. Its subsidiary, West Island Culture is a Dorval, Québec based Health Canada Licence Holder with standard cultivation licence, standard processing, medical sales and sales licences.

Matica continues to work with Yunify Natural Technologies, a Québec based health and personal care research and innovation company to develop proprietary products for Matica and West Island, including topicals and ionic mists.

Matica Enterprises Inc. (MMJ) is down 14.29 per cent and is trading at C$0.03 at 9:38 am PT.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.